Ganciclovir
Active ingredient · 2 therapeutic classes
Sold as CYTOVENE · EYEZIRGAN
- Drug class
- Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors
- Availability
- See label
- Routes
- Intravenous, Ophthalmic
- Markets covered
- 2
- Products on record
- 24
Overview
Ganciclovir is an active pharmaceutical ingredient in the Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors group (J05AB). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 17 | May 22, 2026 |
| CA Canada | Health Canada | 7 | December 15, 2025 |
GBUnited Kingdom· MHRA
17 products
Uses
Treatment of acute herpetic keratitis (dendritic and geographic ulcers).
How to take
CACanada· Health Canada
7 products
Uses
15% is a topical ophthalmic antiviral that is indicated for the treatment of superficial acute herpes simplex keratitis (dendritic ulcers). 1 Pediatrics (<18 years of age) No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.
How to take
Drug interactions
Known interactions involving Ganciclovir. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 288. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL201620006 · revised May 22, 2026
- [2]Health Canada (DPD) · 02530546 · revised March 22, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.